----
Current ValuationThe current P/E ratio is -0.17, above the reasonable range, cheaper than 0.13% of the time in the past 3 years, and the industry ranks 107/606, the industry Median -1.95.
-0.167xP/E
$0.24Stock price
$-1.44Earnings per share
-0.167xP/E
Stock price$0.24Earnings per share$-1.44
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.49x
- Typical range
- -2.90x–-0.84x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -54.69x | 161.61% | $211.20B |
MRNAUSModerna | -27.98x | 16.99% | $88.16B |
CSLLYUSCSL Limited | -26.26x | -- | $67.72B |
NTRAUSNatera | -283.96x | 5.57% | $54.62B |
RVMDUSRevolution Medicines | -22.81x | 61.94% | $40.33B |
ROIVUSRoivant Sciences | -97.37x | 146.69% | $25.92B |
INSMUSInsmed | -39.42x | 75.15% | $23.87B |
BNTXUSBioNTech SE | -11.25x | 18.75% | $21.99B |
BBIOUSBridgebio Pharma | -24.76x | 30.32% | $14.66B |
SMMTUSSummit Therapeutics | -13.79x | 20.06% | $11.81B |
KYMRUSKymera Therapeutics | -30.34x | 8.45% | $10.60B |
MDGLUSMadrigal Pharma | -30.64x | 51.30% | $9.96B |
PCVXUSVaxcyte | -8.96x | 47.91% | $9.54B |
CYTKUSCytokinetics | -9.65x | 7.04% | $8.62B |
TWSTUSTwist Bioscience | -62.14x | 28.63% | $8.50B |
IBRXUSImmunityBio | -8.49x | 151.32% | $8.43B |
SYREUSSpyre Therapeutics | -56.06x | 45.60% | $8.42B |
ARWRUSArrowHead Pharma | -26.30x | 35,923.70% | $8.41B |
PRAXUSPraxis Precision Medicines | -22.56x | 3.71% | $7.65B |
IONSUSIonis Pharma | -12.13x | 49.51% | $6.85B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
